Q4 2024 Earnings Call Transcript February 26, 2025 Vir Biotechnology, Inc. beats earnings expectations. Reported EPS is $-0.76, expectations were $-0.85. Operator: Hello. Welcome to Vir ...

(NASDAQ: IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, today reported financial results for the year ended December 31, 2024 and highlighted recent ...

Among patients with non-small cell lung cancer treated with resection surgery, those classified as stage I vs. stage III had ...

A world-first clinical trial will investigate whether the experimental treatment given to a former Australian of the year can ...

The FDA will issue a decision on odronextamab’s accelerated approval in relapsed/refractory follicular lymphoma by 30 July ...

IMCR's strong balance sheet, with over $800 million in liquid assets, positions them well for future R&D or even a potential ...

Medically reviewed by Marla Anderson, MD HR+/HER2- breast cancer—or hormone receptor-positive, HER2-negative breast cancer—is ...

Hina Khan highlights an important aspect of cancer recovery -- treatment doesn’t always end with chemotherapy or surgery.

Full year 2024 net revenues of $605 million and fourth quarter net revenues of $161 million. Optune Lua® received FDA approval for the treatment of metastatic non-small cell lung ...

At K Hospital’s pathology center, doctors and technicians work tirelessly behind the scenes to provide accurate cancer ...

Patients with metastatic or unresectable gastric cancer are usually given 5-fluorouracil (5-FU) and platinum-based chemotherapy, but patients with advance disease usually have a poor prognosis. The ...

Metformin is widely used to manage type 2 diabetes, but new research suggests it may also help the immune system fight cancer ...